Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1994-07-25
1997-07-15
Achutamurthy, Ponnathapura
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 2, 514 12, 530350, 530856, A61K 3816, A61K 3817, A61K 3558
Patent
active
056483392
ABSTRACT:
Herpoxin, herpes virus inhibitor consists of two proteins isolated from snake venom of Naja n. kaouthia, which separately and together inhibit the replication of herpes simplex viruses type 1 and type 2 in cell cultures. Herpoxin is characterized as a purified component of snake venom, of the phospholipase A.sub.2 (PhA2) enzyme family, which inhibits production of the typical cytopathogenic effects (CPE) produced by herpes viruses type 1 and type 2. Herpoxin consists of two peptides Herp-A and Herp-B having molecular weights 14,000 and 15,000 daltons, respectively, as revealed by gel electrophoresis. The partial sequence for the first fifteen N-terminal amino acids of both Herp-A and Herp-B is: Asn-Leu-Tyr-Gln-Phe-Lys-Asn-Met-Ile-Gln-Cys-Thr-Val-Pro-Asn, which will be referred to as SEQ ID No: 1. The known partial sequences for Herp-A and Herp-B proteins are identical and are typical of phospholipases. However, Herp-A and Herp-B are antigenicaily distinct. Herpoxin is claimed for its method of purification and as a treatment for herpes virus type 1 and type 2 induced oral and genital lesions and other infections. Herpoxin is further claimed as a therapeutic agent for non invasive topical application to treat other viral infections such as: herpes zoster, Kaposi sarcoma in AIDS patents, eczema, etc. It is also an object of this invention to provide Herpoxin as a composition for the treatment of skin infections induced by other microbial agents.
REFERENCES:
Joubert J. and Taljaard, N: "Purification, Some Properties and Amino-Acid Sequences of Two Phospolipases A (CM-II and CM-III) from Naja naja kaouthia Venom", Eur. J. Biochem., 112, pp. 493-499 (1980).
Richter "Clinical Immunology"pp. 25-29, 74-77, 1982, Williams & Wilkens, Baltimore.
Lipps Binie V.
Lipps Frederick W.
Achutamurthy Ponnathapura
Casperson John R.
LandOfFree
Herpoxin: herpes virus inhibitor and method does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Herpoxin: herpes virus inhibitor and method, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Herpoxin: herpes virus inhibitor and method will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1492408